Premium
Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer
Author(s) -
Takahashi Satoru,
Uemura Hiroji,
Seeni Azman,
Tang Mingxi,
Komiya Masami,
Long Ne,
Ishiguro Hitoshi,
Kubota Yoshinobu,
Shirai Tomoyuki
Publication year - 2012
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.22505
Subject(s) - prostate cancer , lncap , telmisartan , androgen receptor , medicine , cancer research , candesartan , endocrinology , bicalutamide , estrogen receptor , angiotensin ii , cancer , oncology , receptor , breast cancer , blood pressure
BACKGROUND With the limited strategies for curative treatment of castration‐resistant prostate cancer (CRPC), public interest has focused on the potential prevention of prostate cancer. Recent studies have demonstrated that an angiotensin II receptor blocker (ARB) has the potential to decrease serum prostate‐specific antigen (PSA) level and improve performance status in CRPC patients. These facts prompted us to investigate the direct effects of ARBs on prostate cancer growth and progression. METHODS Transgenic rat for adenocarcinoma of prostate (TRAP) model established in our laboratory was used. TRAP rats of 3 weeks of age received ARB (telmisartan or candesartan) at the concentration of 2 or 10 mg/kg/day in drinking water for 12 weeks. In vitro analyses for cell growth, ubiquitylation or reporter gene assay were performed using LNCaP cells. RESULTS We found that both telmisartan and candesartan attenuated prostate carcinogenesis in TRAP rats by augmentation of apoptosis resulting from activation of caspases, inactivation of p38 MAPK and down‐regulation of the androgen receptor (AR). Further, microarray analysis demonstrated up‐regulation of estrogen receptor β (ERβ) by ARB treatment. In both parental and androgen‐independent LNCaP cells, ARB inhibited both cell growth and AR‐mediated transcriptional activity. ARB also exerted a mild additional effect on AR‐mediated transcriptional activation by the ERβ up‐regulation. An intervention study revealed that PSA progression was prolonged in prostate cancer patients given an ARB compared with placebo control. CONCLUSION These data provide a new concept that ARBs are promising potential chemopreventive and chemotherapeutic agents for prostate cancer. Prostate 72:1559–1572, 2012. © 2012 Wiley Periodicals, Inc.